News

RenovoRx CEO to Share Insights at Global Investment Conference

RenovoRx CEO to Share Insights at Global Investment Conference

RenovoRx CEO to Present at Global Investment Conference

LOS ALTOS, Calif., Aug. 27, 2024 — RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company recognized for its innovative precision oncology therapies via a local drug-delivery platform, has announced that CEO Shaun Bagai will be presenting at H.C. Wainwright’s 26th Annual Global Investment Conference. This prestigious event is set to take place in New York City from September 9-11, 2024, with Mr. Bagai's presentation scheduled for September 9, 2024, at 7:00 a.m. ET.

In his presentation, Mr. Bagai will showcase the company’s recent achievements, particularly the progress made in RenovoRx’s pivotal ongoing Phase III TIGeR-PaC clinical trial. This trial is crucial for assessing the effectiveness of the company’s proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, which targets the treatment of Locally Advanced Pancreatic Cancer (LAPC).

Presentation Details

Date: Monday, September 9, 2024
Time: 7:00 a.m. ET
Location: Lotte New York Palace Hotel, New York City
Speaker: Shaun Bagai, CEO

Importance of the TIGeR-PaC Clinical Trial

Mr. Bagai will also share insights into RenovoRx's ongoing search for new commercial opportunities related to its proprietary therapy platform technology, particularly the FDA-cleared RenovoCath delivery system, which has the potential to function as a stand-alone device. The RenovoCath device is designed for temporary vessel occlusion in various medical procedures, including arteriography and the infusion of chemotherapeutic drugs. In line with its commercial strategy, RenovoRx appointed Ryan Witt as Senior Vice President of Corporate Strategy and Partnerships in June 2024.

Overview of RenovoRx's Clinical Innovations

RenovoRx is conducting the TIGeR-PaC clinical trial as a Phase III randomized multi-center study that specifically evaluates the TAMP™ platform for the treatment of LAPC. This trial utilizes RenovoRx’s first product candidate that employs TAMP technology, representing a groundbreaking investigational oncology drug-delivery system that incorporates the FDA-cleared RenovoCath device for administering the chemotherapy agent gemcitabine HCl directly to the tumor site.

Interim Analysis and Future Projections

The first interim analysis of the Phase III trial was completed in March 2023. Encouragingly, the Data Monitoring Committee has recommended that the study continue, highlighting the significance of TAMP technology for patients with LAPC. The study aims to achieve a primary endpoint that includes a six-month overall survival benefit while also focusing on minimizing side effects compared to standard treatments. The second interim analysis is expected to coincide with the estimated 52nd event, anticipated to occur in late 2024 or early 2025.

RenovoRx: Company Overview

RenovoRx is committed to developing advanced precision oncology solutions through a unique local drug delivery mechanism designed to address significant unmet medical needs. The TAMP™ therapy platform effectively delivers treatment directly to the tumor site, enhancing therapeutic outcomes while potentially reducing the toxicities typically associated with systemic IV therapy. The company boasts a robust pipeline, including a Phase III lead product candidate that is currently part of a U.S. investigational new drug application under the oversight of regulatory authorities.

Beyond its core clinical activities, RenovoRx is actively exploring commercialization opportunities utilizing its TAMP technology and the RenovoCath delivery system, independent of other oncology applications. RenovoRx remains dedicated to innovatively transforming cancer care and improving patient lives through pioneering therapeutic solutions.

Frequently Asked Questions

What will RenovoRx CEO Shaun Bagai present at the conference?

Mr. Bagai will discuss the company's recent accomplishments and provide insights into its TIGeR-PaC clinical trial, which focuses on treating locally advanced pancreatic cancer.

Where and when is the conference being held?

The H.C. Wainwright’s Global Investment Conference will take place from September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.

What is the significance of the TIGeR-PaC trial?

The TIGeR-PaC trial assesses the effectiveness of the TAMP™ therapy platform in improving treatment outcomes for patients suffering from locally advanced pancreatic cancer.

Who was recently appointed to RenovoRx's Corporate Strategy team?

Ryan Witt was appointed as Senior Vice President of Corporate Strategy and Partnerships in June 2024.

What does the RenovoCath device do?

The RenovoCath device is utilized for temporary vessel occlusion in medical procedures such as arteriography, preoperative occlusion, and chemotherapy drug infusion.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

STRATA Showcases Excimer Laser Success in Dermatology

Updated Category News Views 4

The Cutting Edge of Skin Care: STRATA's Spotlight It's not every day you hear about dermatology shaking things up, but STRATA Skin Sciences, Inc. pulled it off with flair at the 2026 Fall Clinical Dermatology Conference in Las Vegas. For 'skin in the game,' these folks are leading the charge with their innovative excimer laser phototherapy approach, shining a fresh light...

Continue Reading
NCICU's Digital Boost for NC Transfer Students

Updated Category News Views 4

New Platform Eases the Transfer Struggle They’ve finally cooked up something good for the college crowd in North Carolina. The NCICU, with the NCCCS, has rolled out a platform called Transfer Pathways to simplify students' path from two-year to four-year schools. This ain't just a tweak—it's backed by a hefty $2 million in grants. Hats off to those...

Continue Reading
TKO's Bold $2B All-Cash Move for SVC's Hotels

Updated Category News Views 5

TKO's Big, Bold Bid: What Does it Mean? In the crazy world of high-stakes hospitality investments, there are moments that turn heads. TKO's $2 billion all-cash offer to snag Service Properties Trust's prized hotel portfolio is exactly one of those shake-ups. Let's not sugarcoat it; this is a bold move to the big leagues, and it's not without its quirks. A Cash-Infused...

Continue Reading
Morphe’s Auction Hits High Notes with Fine Jewelry

Updated Category News Views 6

Luxurious Gems Steal the Spotlight When the gavel dropped at Morphy's Fine Jewelry & Watches Auction, it set the stage for a spectacular showcase of opulent treasures. The event, highlighting 632 lots and tallying over $1.8 million in sales, left bidders buzzing in anticipation of their next chance to snag a slice of elegance. Bvlgari's Serpentine Charm In the spotlight...

Continue Reading
Duke Energy Braces for Isaias: Key Prep Steps Ahead

Updated Category News Views 4

Brace Yourself: Duke Energy Gears Up for Isaias In the ever-unpredictable game of Mother Nature versus infrastructure, Duke Energy is stepping into the ring once more, readying to tackle potential outages across the Carolinas as Hurricane Isaias edges near. Listen, if there's one thing I've learned over years of watching these weather events unfold on the stock ticker and...

Continue Reading
Ingram Mercantile's Aviation Push: SCORE or Sink?

Updated Category News Views 5

Unpacking Neobanx's Strategic Play Straight off the tarmac, Neobanx launches Ingram Mercantile, placing their bets on the aviation sector with none other than Eli Stepp at the helm. This ain't just another day in the sky for those in the know; it's part of a gutsy bid to inject some high-octane intelligence into the world of retail. I mean, have you seen the landscape...

Continue Reading
Mastering Packaging Costs: Beyond the Box Price

Updated Category News Views 4

Peeling Back the Layers of Packaging Costs Packaging's a bit like an onion—every layer you peel back reveals another cost you didn’t see at first glance. Folks in the know, like Kyle Reger of Jamestown Container Companies, are flipping the script on how we approach packaging expenses. It's not just about snagging the cheapest box on the shelf anymore. There's a whole...

Continue Reading
CellFiber Expands to Philly: Boosting US Biotech Scene

Updated Category News Views 5

CellFiber's Leap into 'Cellicon Valley' Folks, when the biotech winds start blowing, you better have your sails up. CellFiber Co., Ltd., a Tokyo-based innovator, has landed itself a comfy spot in the City of Brotherly Love. We're talking Philadelphia, folks, or, as it's dubbed in certain circles, 'Cellicon Valley.' Now if that's not a name that screams biotech pedigree, I...

Continue Reading
Armor Health Strengthens Corrections Care with New Leader

Updated Category News Views 3

Fresh Blood in Correctional Healthcare Talk about stepping up where it counts! Armor Health is shaking things up, bringing in Jill Bromley as their new Regional Behavioral Health Director. The name might not ring any bells for the average Joe, but in the world of correctional healthcare, it’s like they've just upgraded from a sedan to a sports car. Armor’s game here...

Continue Reading
Strategic Move: Chimney Collective Teams with Four Winds

Updated Category News Views 5

A Partnership Fueled by Legacy and Growth In the world of brick, mortar, and flue, a big play just unfolded. Chimney Collective, flexing its investment muscle, has hitched its wagon to Four Winds Chimney, a company that's carved out quite a niche in New York's chimney scene. We're not talking about a corporate takeover here; this is about putting money where growth and...

Continue Reading

Top 5 Most Recently Viewed Articles

Grewal Law Advocates for Victims' Rights in Education Systems

Updated Category News Views 146

Grewal Law Advocates for Victims' Rights in Education Systems In recent discussions, Grewal Law has highlighted the significance of addressing sexual abuse within educational environments. As a leading law firm recognized for its dedication to justice, Grewal Law is deeply committed to helping victims of sexual abuse navigate the complexities that often accompany legal...

Continue Reading
Dyadic International, Inc. Announces New Stock Offering Plans

Updated Category News Views 92

Dyadic International, Inc.: Overview of Recent Stock Offering Dyadic International, Inc. is making waves in the biotechnology sector with its recent announcement regarding a public offering. The company has detailed plans for the pricing of 6,052,000 shares of common stock, which is priced at $0.95 per share. Financial Expectations from the Offering The anticipated gross...

Continue Reading
Corsair Gaming Reports Stellar Earnings and Stock Surge

Updated Category News Views 208

Stellar Earnings Propel Corsair Stock Corsair Gaming shares have recently surged impressively, rising significantly following an outstanding quarterly earnings report. This growth has caught the attention of investors and analysts alike. Impressive Financial Performance In the fourth quarter, Corsair reported adjusted earnings per share of 43 cents, significantly...

Continue Reading
Tim Woodward: CNN Hero For Animal Rescue Leadership

Updated Category News Views 278

Tim Woodward Celebrated as a CNN Hero for Animal Welfare The leadership of Tim Woodward, the executive director of the national nonprofit Animal Rescue Corps, has gained significant recognition as he is honored as a CNN Hero. This acknowledgment is a testament to his unwavering dedication and commitment to the welfare of animals across the United States. Dedication to...

Continue Reading
Investigation Launched into 374Water Inc. for Shareholder Rights

Updated Category News Views 195

Investigation into 374Water Inc. by Attorneys Purcell & Lefkowitz LLP has taken steps to investigate 374Water Inc. (NASDAQ: SCWO), focusing on the company's directors and their recent decisions regarding shareholder interests. The law firm aims to uncover potential breaches of fiduciary duties that could have negatively affected investors. Understanding Shareholder Rights...

Continue Reading